Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy

Table 3

Overall survival by performance status, histology, and stage.

		Patients ()	Median OS (months)	95% confidence interval
				Lower	Upper
All patients		245	9.4	7.8	12.0
Eastern Cooperative Oncology Group (ECOG) performance status	0, 1	154	13.7	12.1	15.1
	2	51	4.0	2.3	6.7
	3, 4	21	2.0	0.8	3.6
Histology	Epithelial	154	12.5	9.3	14.4
	Sarcomatoid	34	4.5	2.0	6.9
	Mixed	27	8.1	4.5	12.1
Stage	I	84	13.6	9.0	16.0
	II	20	6.7	2.0	20.8
	III	69	9.3	7.0	14.2
	IV	63	7.4	4.0	9.9